JP2019524860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524860A5 JP2019524860A5 JP2019511454A JP2019511454A JP2019524860A5 JP 2019524860 A5 JP2019524860 A5 JP 2019524860A5 JP 2019511454 A JP2019511454 A JP 2019511454A JP 2019511454 A JP2019511454 A JP 2019511454A JP 2019524860 A5 JP2019524860 A5 JP 2019524860A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- dose
- pharmaceutical composition
- composition according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims 36
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 14
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 14
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 14
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 claims 1
- 238000011278 co-treatment Methods 0.000 claims 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380004P | 2016-08-26 | 2016-08-26 | |
| US62/380,004 | 2016-08-26 | ||
| PCT/EP2017/071418 WO2018037109A1 (en) | 2016-08-26 | 2017-08-25 | Treatment of nonalcoholic fatty liver disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524860A JP2019524860A (ja) | 2019-09-05 |
| JP2019524860A5 true JP2019524860A5 (cg-RX-API-DMAC7.html) | 2020-10-01 |
| JP7048863B2 JP7048863B2 (ja) | 2022-04-06 |
Family
ID=59699703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511454A Active JP7048863B2 (ja) | 2016-08-26 | 2017-08-25 | 非アルコール性脂肪肝疾患の治療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11179384B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3503892A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7048863B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110099686B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017317575B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3034956C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018037109A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001238288A1 (en) | 2000-02-16 | 2001-08-27 | University Of Nebraska Medical Center | Method and compositions for treating fibrotic diseases |
| RS53543B1 (sr) * | 2004-03-03 | 2015-02-27 | Takeda Gmbh | Novi hidroksi-6-heteroarilfenantridini i njihova primena kao pde4 inhibitori |
| CN101133045A (zh) * | 2005-03-02 | 2008-02-27 | 尼科梅德有限责任公司 | 6-杂环基取代的六氢菲啶衍生物的新盐类 |
| KR101421914B1 (ko) | 2005-03-02 | 2014-07-22 | 다케다 게엠베하 | 6-헤테로시클릴 치환된 헥사히드로페난트리딘 유도체의 신규한 염 |
| NZ574710A (en) * | 2006-09-07 | 2012-02-24 | Nycomed Gmbh | Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus |
| WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
| WO2009154230A1 (ja) * | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| EP3096760A1 (en) * | 2014-01-22 | 2016-11-30 | Takeda GmbH | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
| ES2749433T3 (es) * | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática |
| EP3328381A1 (en) * | 2015-07-29 | 2018-06-06 | Takeda GmbH | Pde4 inhibitor for the treatment of diabetic nephropathy |
-
2017
- 2017-08-25 US US16/328,620 patent/US11179384B2/en active Active
- 2017-08-25 CA CA3034956A patent/CA3034956C/en active Active
- 2017-08-25 EP EP17757545.3A patent/EP3503892A1/en not_active Withdrawn
- 2017-08-25 AU AU2017317575A patent/AU2017317575B2/en active Active
- 2017-08-25 CN CN201780062867.1A patent/CN110099686B/zh active Active
- 2017-08-25 JP JP2019511454A patent/JP7048863B2/ja active Active
- 2017-08-25 WO PCT/EP2017/071418 patent/WO2018037109A1/en not_active Ceased